Ignacio Garcia‐Ribas

893 total citations
33 papers, 654 citations indexed

About

Ignacio Garcia‐Ribas is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ignacio Garcia‐Ribas has authored 33 papers receiving a total of 654 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Ignacio Garcia‐Ribas's work include Cancer Immunotherapy and Biomarkers (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Treatment and Pharmacology (7 papers). Ignacio Garcia‐Ribas is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Treatment and Pharmacology (7 papers). Ignacio Garcia‐Ribas collaborates with scholars based in Spain, United States and Germany. Ignacio Garcia‐Ribas's co-authors include Éric Charpentier, Beth A. Hellerstedt, Michael Danso, Paul Richards, Jennifer M. Specht, Denise A. Yardley, Lee Schwartzberg, Mansoor N. Saleh, Nicholas J. Robert and Richard S. Finn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Ignacio Garcia‐Ribas

32 papers receiving 636 citations

Peers

Ignacio Garcia‐Ribas

ONCOL

GENET

PRM

Maria Chiara Scaini Italy

Maria Unni Rømer Denmark

Tiago O. Botelho Portugal

Fabien Gay France

Nathalie Dugot‐Senant France

Tze‐Sian Chan Taiwan

David Browell United Kingdom

Catherine E. Willoughby Spain

Noëlla Blétard Belgium

Claus Fittschen United States

Maria Chiara Scaini Italy

Ignacio Garcia‐Ribas

252 ×0.6

ONCOL

286 ×1.4

47 ×0.3

GENET

67 ×0.5

PRM

131 ×1.3

Citations per year, relative to Ignacio Garcia‐Ribas Ignacio Garcia‐Ribas (= 1×) peers Maria Chiara Scaini

Countries citing papers authored by Ignacio Garcia‐Ribas

Since Specialization

Citations

This map shows the geographic impact of Ignacio Garcia‐Ribas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Garcia‐Ribas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Garcia‐Ribas more than expected).

Fields of papers citing papers by Ignacio Garcia‐Ribas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ignacio Garcia‐Ribas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Garcia‐Ribas. The network helps show where Ignacio Garcia‐Ribas may publish in the future.

Co-authorship network of co-authors of Ignacio Garcia‐Ribas

This figure shows the co-authorship network connecting the top 25 collaborators of Ignacio Garcia‐Ribas. A scholar is included among the top collaborators of Ignacio Garcia‐Ribas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ignacio Garcia‐Ribas. Ignacio Garcia‐Ribas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cohen, Roger B., Antonio Jimeno, Lova Sun, et al.. (2025). Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors. Investigational New Drugs. 43(3). 609–620.

Torres-Jiménez, Javier, Mariano Ponz‐Sarvisé, Bruno Bockorny, et al.. (2025). First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors.. Journal of Clinical Oncology. 43(16_suppl). 3028–3028. 2 indexed citations

Cutsem, Eric Van, Joëlle Collignon, Rikke Løvendahl Eefsen, et al.. (2024). Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer. Clinical Cancer Research. 30(23). 5293–5303. 2 indexed citations

Ghosh, Maloy, et al.. (2023). 719 Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers. SHILAP Revista de lepidopterología. A814–A814. 1 indexed citations

Kuboki, Yasutoshi, Toshio Shimizu, Kan Yonemori, et al.. (2022). Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer Research Communications. 2(11). 1426–1435. 7 indexed citations

Zvirbule, Zanete, Luis Paz‐Ares, Ahmad Awada, et al.. (2022). Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 40(16_suppl). 9020–9020. 6 indexed citations

Dièras, Véronique, Hervé Bonnefoi, Emilio Alba, et al.. (2019). Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. Breast Cancer Research and Treatment. 177(2). 383–393. 12 indexed citations

Mearns, Elizabeth S., et al.. (2018). Gastrointestinal Adverse Events with Combination of Checkpoint Inhibitors in Advanced Melanoma: A Systematic Review. SHILAP Revista de lepidopterología. 5(1). MMT01–MMT01. 11 indexed citations

Novello, Silvia, Benjamin Besse, Enriqueta Felip, et al.. (2014). A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. Annals of Oncology. 25(11). 2156–2162. 27 indexed citations

10.

O’Shaughnessy, Joyce, Lee Schwartzberg, Michael Danso, et al.. (2014). Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology. 32(34). 3840–3847. 229 indexed citations

11.

Llombart‐Cussac, Antonio, Aňa Lluch, Cristian Villanueva, et al.. (2012). SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 30(15_suppl). 1011–1011. 7 indexed citations

12.

Pérez‐Torras, Sandra, Meritxell Carrió, Anna Cascante, et al.. (2011). Connexin-26 Is a Key Factor Mediating Gemcitabine Bystander Effect. Molecular Cancer Therapeutics. 10(3). 505–517. 30 indexed citations

13.

Shonukan, Oluwatoyin, et al.. (2009). Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas. 3(1). 1 indexed citations

14.

Veltkamp, Stephan A., Robert W. Jansen, Ignacio Garcia‐Ribas, et al.. (2007). Gemcitabine metabolite, 2’,2’-difluorodeoxyuridine (dFdU), can be phosphorylated and incorporated into nucleic acids. Cancer Research. 67. 1541–1541. 1 indexed citations

15.

Carles, Joan, Emilio Esteban, José A. Martínez-Climent, et al.. (2007). Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Annals of Oncology. 18(8). 1359–1362. 47 indexed citations

16.

Perez‐Gracia, José Luis, María del Mar Muñoz, Grant Williams, et al.. (2005). Assessment of the value of confirming responses in clinical trials in oncology. European Journal of Cancer. 41(11). 1528–1532. 7 indexed citations

17.

Perez‐Gracia, José Luis, et al.. (2002). The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research. Cancer. 95(7). 1605–1610. 17 indexed citations

18.

Castleden, Simon, Heung Chong, Ignacio Garcia‐Ribas, et al.. (1997). A Family of Bicistronic Vectors to Enhance Both Local and Systemic Antitumor Effects of HSVtk or Cytokine Expression in a Murine Melanoma Model. Human Gene Therapy. 8(17). 2087–2102. 37 indexed citations

19.

Melcher, Alan, Ignacio Garcia‐Ribas, & R G Vile. (1997). Personal paper: Gene therapy for cancer—managing expectations. BMJ. 315(7122). 1604–1607. 4 indexed citations

20.

Mayordomo, José, Fernando Rivera, P. Lianes, et al.. (1995). Improving Treatment of Chemotherapy-Induced Neutropenic Fever by Administration of Colony-Stimulating Factors. JNCI Journal of the National Cancer Institute. 87(11). 803–808. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact